TL;DR: Aetna, a CVS Health company, modified CPB 0705 covering body surface potential mapping, effective November 26, 2025. The policy classifies this technology as experimental, investigational, or unproven across all listed cardiac indications — meaning claims billed under CPT codes 0695T and 0696T are likely to be denied for Aetna members.
Body surface potential mapping billing just got more defined — and not in a direction that helps your revenue cycle. Aetna updated CPB 0705 to address five specific cardiac indications, explicitly classifying each as experimental, investigational, or unproven. The two codes that take the direct hit are 0695T and 0696T, the Category III CPT codes for body surface-activation mapping of pacemaker and implantable cardioverter-defibrillator leads. If your cardiology or electrophysiology group bills these codes for Aetna members, expect denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Body Surface Potential Mapping — CPB 0705 |
| Policy Code | CPB 0705 |
| Change Type | Modified |
| Effective Date | November 26, 2025 |
| Impact Level | Medium — targeted codes are Category III, but denial risk is high for EP and device-heavy practices |
| Specialties Affected | Cardiology, Electrophysiology, Cardiac Electrophysiology, Cardiac Device Clinics |
| Key Action | Flag CPT 0695T and 0696T in your charge capture as non-covered for Aetna members and update denial management workflows before billing these codes |
Aetna Body Surface Potential Mapping Coverage Criteria 2025
The Aetna body surface potential mapping coverage policy is straightforward: there is no covered indication. Aetna considers body surface potential mapping (also called body surface mapping) experimental, investigational, or unproven for all of the listed cardiac conditions. The policy lists five explicit indications, and all five carry that designation.
The classification of experimental, investigational, or unproven is the controlling language in CPB 0705. That is the exact terminology Aetna uses — not "not medically necessary." These are distinct classifications, and the distinction matters when you're preparing documentation or communicating with your clinical team.
For information on appeal rights and prior authorization processes specific to this policy, consult Aetna's provider manual or contact Aetna Provider Services directly.
Aetna Body Surface Potential Mapping Exclusions and Non-Covered Indications
Aetna CPB 0705 lists five indications where body surface potential mapping is explicitly considered experimental, investigational, or unproven. None are covered under this policy.
The five excluded indications are:
| # | Excluded Procedure |
|---|---|
| 1 | Acute coronary syndromes — including acute cardiac ischemia and myocardial infarction |
| 2 | Atrial fibrillation — evaluation |
| 3 | Brugada syndrome — evaluation |
| 4 | Atrial fibrillation ablation — guidance during the procedure |
| 5 | Cardiac resynchronization therapy — prediction of patient response |
The breadth here matters. This isn't one niche use case. It covers the most common reasons a cardiac electrophysiology practice might order or perform body surface mapping — from pre-procedural planning for AF ablation to CRT optimization. All of them fall under the experimental, investigational, or unproven designation.
The policy notes this list is "not all-inclusive." That's a red flag for any adjacent indication your team might think falls outside these five categories. Aetna's position is that the technology itself lacks established effectiveness. Don't assume an unlisted indication will be treated differently.
Coverage Indications at a Glance
| Indication | Coverage Status | Notes |
|---|---|---|
| Acute coronary syndromes (acute cardiac ischemia, myocardial infarction) | Not Covered — Experimental, Investigational, or Unproven | Claims for these indications are likely to be denied |
| Atrial fibrillation — evaluation | Not Covered — Experimental, Investigational, or Unproven | Includes diagnostic evaluation for AF |
| Brugada syndrome — evaluation | Not Covered — Experimental, Investigational, or Unproven | No coverage under CPB 0705 |
| Atrial fibrillation ablation — guidance | Not Covered — Experimental, Investigational, or Unproven | Includes use during ablation procedures |
| Cardiac resynchronization therapy — response prediction | Not Covered — Experimental, Investigational, or Unproven | CRT optimization mapping not covered |
| Any unlisted indication | Not Covered — Policy is not all-inclusive | Aetna's position covers unenumerated indications |
CPT codes 0695T and 0696T are listed under "CPT codes not covered for indications listed in the CPB." These are the primary billing codes affected by CPB 0705.
Aetna Body Surface Potential Mapping Billing Guidelines and Action Items 2025
The real issue here is that practices performing device optimization or AF ablation may be using body surface mapping as part of a broader procedure — and billing 0695T or 0696T as an add-on. Those claims are likely to be denied under the updated CPB 0705, effective November 26, 2025. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Flag CPT 0695T and 0696T as non-covered for Aetna in your charge capture system. Do this before your next billing cycle. Both codes are explicitly listed under "CPT codes not covered for indications listed in the CPB." A hard stop in charge capture prevents claims from going out the door. |
| 2 | Audit claims submitted after November 26, 2025 for 0695T and 0696T billed to Aetna. Pull any that already went out and check their status. If they're still pending, prepare your denial management team. |
| 3 | Update your denial management and appeal templates. The source policy classifies body surface potential mapping as experimental, investigational, or unproven for all listed indications. For information on appeal rights, consult Aetna's provider manual or contact Aetna Provider Services directly. Redirect your team's effort toward identifying whether a covered alternative service was actually performed and documentable. |
| 4 | Communicate the change to your electrophysiology and cardiac device teams. Physicians ordering or performing body surface mapping for AF ablation guidance or CRT optimization need to know this technology won't generate reimbursement from Aetna. This is a clinical workflow conversation, not just a billing one. |
| 5 | Review your broader procedure billing for claims that include 0695T or 0696T. If your team performs pacemaker or ICD-related procedures — codes like 33208, 33224, 33225, 33249, or similar device codes listed in CPB 0705 — and body surface mapping was also billed, review those claims carefully. Note: CPB 0705 contains no explicit bundling rules. This is general RCM practice guidance, not an Aetna policy statement. If you have specific questions about how Aetna treats these combinations, contact Aetna Provider Services. |
| 6 | Check related policy CPB 0664. Aetna cross-references CPB 0664 for Signal-Averaged Electrocardiography (SAECG). If your practice bills SAECG alongside cardiac procedures, review CPB 0664 for separate coverage rules. They're distinct technologies with distinct policy treatment. |
| 7 | If you're uncertain how this applies to your payer mix, talk to your compliance officer before billing these codes. The policy's "not all-inclusive" language on excluded indications creates ambiguity for edge cases. Your compliance officer should weigh in on how broadly to apply the exclusion. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Body Surface Potential Mapping Under CPB 0705
Not Covered — Experimental CPT Codes
These two codes are the primary billing targets of CPB 0705. Aetna classifies these codes as not covered for the indications listed in the policy.
| Code | Type | Description |
|---|---|---|
| 0695T | CPT (Category III) | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize pacing parameters |
| 0696T | CPT (Category III) | Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize pacing parameters (additional code — see full descriptor) |
HCPCS Codes
The policy references 4 HCPCS codes. The specific code descriptions were not available in the policy data reviewed. Access the full CPB 0705 policy document directly from Aetna for the complete HCPCS code list.
ICD-10-CM Diagnosis Codes
The policy references 53 ICD-10-CM diagnosis codes. The specific codes were not available in the policy data reviewed. Work with your coding team and access the full CPB 0705 policy document directly from Aetna to get the complete ICD-10 code list.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.